Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV)
Background Adeno‐associated virus (AAV) is a human parvovirus currently being developed as a vector for gene therapy applications. Traditionally AAV has been purified from cell lysates using CsCl gradients; this approach however is not likely to be useful in large‐scale manufacturing. Moreover gradi...
Gespeichert in:
Veröffentlicht in: | The journal of gene medicine 2000-11, Vol.2 (6), p.444-454 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Adeno‐associated virus (AAV) is a human parvovirus currently being developed as a vector for gene therapy applications. Traditionally AAV has been purified from cell lysates using CsCl gradients; this approach however is not likely to be useful in large‐scale manufacturing. Moreover gradient‐purified AAV vectors tend to be contaminated with significant levels of cellular and adenoviral proteins and nucleic acid. To address the issue of purification we have developed a process scale method for the rapid and efficient purification of recombinant AAV (rAAV) from crude cellular lysates.
Methods
The preferred method for the purification of rAAVβgal includes treatment of virally infected cell lysates with both trypsin and nuclease followed by ion exchange chromatography using ceramic hydroxyapatite and DEAE‐Sepharose in combination with cellufine sulphate affinity chromatography.
Results
Purification of rAAV particles from crude cellular lysates co‐infected with adenovirus was achieved using column chromatography exclusively. Column‐purified rAAV was shown to be greater than 90% pure, free of any detectable contaminating adenovirus, biologically active, and capable of directing efficient gene transfer to the lungs of both cotton rats and mice.
Conclusions
This study demonstrates the feasibility of using column chromatography alone for the isolation of highly purified rAAV vector. The methods described here are advancements in procedures to purify rAAV and are adaptable for commercial production of clinical‐grade rAAV vector. Copyright © 2000 John Wiley & Sons, Ltd. |
---|---|
ISSN: | 1099-498X 1521-2254 |
DOI: | 10.1002/1521-2254(200011/12)2:6<444::AID-JGM132>3.0.CO;2-1 |